NEW YORK, NY--(Marketwired - Apr 19, 2017) - NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company, today announces the publication of an editorial featuring TapImmune, Inc. (NASDAQ: TPIV), an NNW client focused on leading the field of oncology with its next-generation T-cell vaccines and novel immunotherapy platforms.

The publication is entitled, "Positive News in the Fight against Cancer Fuels Quest for More Good Tidings." It discusses the advancements in cancer treatment options and highlights multiple innovative biopharma companies with a focus on oncology.

To view the full publication, visit: https://www.networknewswire.com/positive-news-fight-cancer-fuels-quest-good-tidings/

"TapImmune's immunotherapies take the unique approach of targeting both metastatic disease and tumors. The primary cause of death among cancer patients is not the primary tumor but metastatic disease, or the spreading of cancer to untreatable areas of the body. TapImmune's therapies have advanced beyond the abilities of earlier vaccine approaches by treating both tumors and metastatic diseases, and TapImmune's work is further distinguished by its approach of activating a patient's own immune system in fighting cancer.

"TapImmune's next-generation technology is able to standalone as a powerful therapy or be combined with other immunotherapies. The company is currently developing two vaccines that merge proprietary peptide antigen sets designed to invoke both killer T-cell (CD8) and helper T-cell (CD4) immune responses against specific proteins present on the surface of most target tumor cells. The naturally processed antigens in these vaccines are derived from human immune responses that are recognized by over 85 percent of the population. This enables TapImmune to direct a uniquely strong and durable anti-tumor immune response across a broader patient population."

About TapImmune, Inc.
TapImmune, Inc. is a leader in the immunotherapy of woman's cancers advancing multiple Phase 2 and Phase 1b/2 clinical studies for the treatment of ovarian and breast cancer. The company's peptide or nucleic acid-based immunotherapeutics, comprise one or multiple naturally processed epitopes (NPEs) designed to comprehensively stimulate a patient's killer T-cells, helper T-cells and to restore or further augment antigen presentation by using proprietary nucleic acid-based expression systems. The company's technologies may be used as stand-alone medications or in combination with current treatment modalities.

For more information, visit www.tapimmune.com

About NetworkNewsWire
NetworkNewsWire (NNW) provides news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of journalists and contributing writers, NNW is uniquely positioned to best serve private and public companies who need to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today's market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

For more information, visit https://www.NetworkNewsWire.com

Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://nnw.fm/Disclaimer

Forward-Looking Statements
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company's SEC filings. These risks and uncertainties could cause the company's actual results to differ materially from those indicated in the forward-looking statements.